Skip to main content

Developments and Recent Trends in Cell and Gene Therapies for Cancer

  • 1st Edition - March 1, 2027
  • Latest edition
  • Editors: Ranjita Shegokar, Yashwant Pathak
  • Language: English

Developments and Recent Trends in Cell and Gene Therapies for Cancer is a comprehensive and strategic reference that explores the scientific foundations, clinical applic… Read more

Back to School

Start strong. Study with purpose.

Save up to 25% on trusted learning resources

Description

Developments and Recent Trends in Cell and Gene Therapies for Cancer is a comprehensive and strategic reference that explores the scientific foundations, clinical applications, and commercial success of FDA-approved cell and gene therapies. Each chapter focuses on a specific FDA-approved cell or gene therapy product, detailing its development journey, mechanism of action, therapeutic indications, clinical outcomes, regulatory approval, visual data (minimum 4 figures and 3 tables per chapter) and real-world outcomes. The therapies span a wide range of modalities including CAR-T cells, cord blood-derived products, gene editing technologies, and viral vector-based treatments. The chapters are authored by subject matter experts from academia, clinical institutions, and industry, ensuring authoritative and up-to-date content. With contributions from leading experts in academia and industry, the book highlights innovations in CAR-T, cord blood, and gene editing technologies, featuring therapies from companies such as Bristol-Myers Squibb, Pfizer, and Janssen. Designed with modular chapters and rich visual content, it serves both as a scientific resource and a practical guide for oncologists, researchers, biotech professionals, and regulatory stakeholders navigating the evolving landscape of cancer treatment.

Key features

  • Focuses on a single FDA-approved therapy, offering a consistent and detailed format that includes development history, mechanism of action, clinical indications, and outcomes—making it easy for readers to find targeted, actionable insights
  • Bridges foundational science with commercialization pathways, regulatory considerations, and translational challenges—ideal for both researchers and biotech professionals
  • Ensures authoritative content and diverse perspectives, enhancing its value as a reference for oncology, drug development, and policy-making

Readership

Biomedical and Pharmaceutical Researchers focused on oncology, gene editing, cell-based therapies, and translational medicine

Table of contents

1. ABECMA (idecabtagene vicleucel)

2. ADSTILADRIN (nadofaragene firadenovec-vcng)

3. ALLOCORD (HPC, Cord Blood)

4. AMTAGVI (lifileucel)

5. AUCATZYL (obecabtagene autoleucel)

6. BEQVEZ (fidanacogene elaparvovec-dzkt)

7. BREYANZI (lisocabtagene maraleucel)

8. CARVYKTI (ciltacabtagene autoleucel)

9. CASGEVY (exagamglogene autotemcel [exa-cel])

10. CLEVECORD (HPC Cord Blood)

11. DUCORD (HPC Cord Blood)

12. ELEVIDYS (delandistrogene moxeparvovec-rokl)

13. ENCELTO (revakinagene taroretcel-lwey)

14. GINTUIT (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen)

15. HEMACORD (HPC, Cord Blood)

16. HEMGENIX (etranacogene dezaparvovec-drlb)

17. HPC, Cord Blood – Clinimmune Labs

18. HPC, Cord Blood – MD Anderson Cord Blood Bank

19. HPC, Cord Blood – LifeSouth

20. HPC, Cord Blood – Bloodworks

21. IMLYGIC (talimogene laherparepvec)

22. KEBILIDI (eladocagene exuparvovec-tneq)

Product details

  • Edition: 1
  • Latest edition
  • Published: March 1, 2027
  • Language: English

About the editors

RS

Ranjita Shegokar

Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Currently, she serves as Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited many trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received many prestigious national and international awards among them include recently received prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting and the role of excipients in delivery systems. (www.ranjitas.com)

Affiliations and expertise
Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Free University of Berlin, Germany

YP

Yashwant Pathak

Yashwant Pathak is a Professor at Taneja College of Pharmacy at the University of South Florida, FL, United States. His area of research is nanotechnology, drug delivery systems, and nutraceuticals. He is also an Ad junct Professor at the Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia.
Affiliations and expertise
Taneja College of Pharmacy, University of South Florida, Tampa, FL, USA